Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Batoclimab in Generalized Myasthenia Gravis
NCT05403541Phase 3Terminated
- Sponsor
- Immunovant, Inc.
- Start
- Jun 2022
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 3 trial of batoclimab in myasthenia gravis (MG), sponsored by Immunovant, Inc.. Started Jun 2022; status: terminated.
02
Drugs
batoclimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT05403541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05403541.